This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Prothena (PRTA) Alzheimer's Disease Drug Licensed by BMY
by Zacks Equity Research
Prothena (PRTA) will receive $55 million from Bristol Myers Squibb for an exclusive worldwide license to PRX005, designed for the potential treatment of Alzheimer's disease.
BIIBNegative Net Change BMYPositive Net Change LGNDPositive Net Change PRTAPositive Net Change
biotechnology biotechs pharmaceuticals
Novartis (NVS) Entresto Patent Faces Setback, Stock Down
by Zacks Equity Research
Novartis (NVS) faces a setback in the patent litigation with respect to the blockbuster heart disease drug Entresto. Shares decline.
NVSPositive Net Change LGNDPositive Net Change ABBVNegative Net Change BLCOPositive Net Change
biotechnology pharmaceuticals
Axsome (AXSM) Doses First Patient in Late-Stage ADHD Study
by Zacks Equity Research
Axsome (AXSM) doses its first patient in the late-stage, label expansion study of solriamfetol for treating attention deficit hyperactivity disorder.
NVSPositive Net Change JAZZNegative Net Change AXSMPositive Net Change AKRONegative Net Change
biotechnology medical
Zacks.com featured highlights include Phathom Pharmaceuticals, Universal Stainless & Alloy Products and Arlo Technologies
by Zacks Equity Research
Phathom Pharmaceuticals, Universal Stainless & Alloy Products and Arlo Technologies are part of the Zacks Screen of the Week article.
USAPPositive Net Change ARLOPositive Net Change PHATNegative Net Change
biotechnology computers
Novavax's (NVAX) COVID Jab Gets Full Approval in Europe
by Zacks Equity Research
Novavax's (NVAX) protein-based COVID-19 vaccine, Nuvaxovid, gets full marketing authorization for COVID patients in Europe.
PFEPositive Net Change MRNANegative Net Change NVAXNegative Net Change BNTXNegative Net Change
biotechnology medical
JetBlue Airways (JBLU) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
JBLUNo Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Company News for Jul 7, 2023
by Zacks Equity Research
Companies in The News Are: JBLU, AAL, F, MRNA, GENI.
FPositive Net Change JBLUNo Net Change MRNANegative Net Change AALNegative Net Change GENINegative Net Change
airlines auto-tires-trucks biotechnology internet-content
Caribou Biosciences (CRBU) Soars on $25M Investment by Pfizer
by Zacks Equity Research
Caribou Biosciences (CRBU) gets a major boost with a $25 million equity investment by Pfizer, which will accelerate the development of its allogeneic CAR-T cell therapy pipeline.
PFEPositive Net Change ALKSPositive Net Change LGNDPositive Net Change CRBUNegative Net Change
biotechnology biotechs
Biotech Stock Roundup: BMRN's Gene Therapy Gets Approval, SGTX Up on Buyout by LLY
by Zacks Equity Research
Regulatory and acquisition updates from BioMarin (BMRN) and Sigilon (SGTX) are in focus in the biotech sector.
BMRNPositive Net Change LLYPositive Net Change MRNANegative Net Change AMRXNegative Net Change
biotechnology biotechs
The Zacks Analyst Blog Highlights Apple, Verizon Communications, Amgen, Charles Schwab and The Cigna Group
by Zacks Equity Research
Apple, Verizon Communications, Amgen, Charles Schwab and The Cigna Group are part of the Zacks top Analyst Blog.
AAPLPositive Net Change VZPositive Net Change AMGNNegative Net Change SCHWPositive Net Change CINegative Net Change
biotechnology communications computers finance insurance
Regeneron (REGN) Loses 13% in Three Months: What Lies Ahead?
by Zacks Equity Research
Regeneron (REGN) declines 13% in the last three months due to regulatory setback for 8 mg dose strength of aflibercept and competition for lead drug.
REGNPositive Net Change SNYNegative Net Change RHHBYPositive Net Change BAYRYNegative Net Change
biotechnology pharmaceuticals
Kite Realty Group (KRG) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
KRGPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Here's Why You Should Add Alkermes (ALKS) to Your Portfolio
by Zacks Equity Research
Alkermes (ALKS), a top-ranked stock, has a diverse portfolio of neurological therapies. Its proprietary products are witnessing incremental sales.
NVSPositive Net Change MRKNegative Net Change ALKSPositive Net Change AKRONegative Net Change
biotechnology medical
Aurinia (AUPH) Up on Paving the Way for a Potential Buyout
by Zacks Equity Research
Aurinia (AUPH) surges as management decides to explore strategic business options, including potential sale or a merger.
NVSPositive Net Change AUPHNegative Net Change AKRONegative Net Change
biotechnology medical
Velocity Financial (VEL) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
VELNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Immunome (IMNM) Surges on Merger Agreement With Morphimmune
by Zacks Equity Research
Immunome's (IMNM) shares rise following its announcement to merge with Morphimmune. The synergy will help strengthen the development of oncology therapies.
NVSPositive Net Change AKRONegative Net Change IMNMNegative Net Change
biotechnology medical
Bristol Myers' (BMY) Opdivo With Chemo Gets EC Nod for NSCLC
by Zacks Equity Research
Bristol Myers' (BMY) Opdivo, in combination with chemotherapy, gains European Commission approval for neoadjuvant treatment of non-small cell lung cancer, offering new hope for reducing recurrence risk.
NVSPositive Net Change BMYPositive Net Change MRKNegative Net Change LGNDPositive Net Change
biotechnology pharmaceuticals
Esperion (ESPR) to Expand Nilemdo and Nustendi Label in Europe
by Zacks Equity Research
Esperion (ESPR) files type II(a) variation application for expanded use of Nilemdo and Nustendi in Europe to reduce cardiovascular risk.
NVSPositive Net Change ESPRNegative Net Change AKRONegative Net Change
biotechnology medical
Axsome (AXSM) Down on Public Offering of Common Stock
by Zacks Equity Research
Axsome (AXSM) is set to issue secondary shares, which will significantly dilute its current shareholder base. Consequently, share price declines.
NVSPositive Net Change AXSMPositive Net Change AKRONegative Net Change
biotechnology medical
Booz Allen Hamilton (BAH) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
BAHPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Company News for Jun 29, 2023
by Zacks Equity Research
Companies in The News Are: AVAV, UNF, GIS, ROIV.
GISNegative Net Change UNFPositive Net Change AVAVPositive Net Change ROIVPositive Net Change
aerospace biotechnology consumer-staples industrial-products
Biotech Stock Roundup: SRPT's DMD Therapy Approval, ICPT's Setback & More Updates
by Zacks Equity Research
Regulatory updates from Sarepta (SRPT) and Intercept (ICPT) are in focus in the biotech sector.
BMYPositive Net Change SRPTNegative Net Change ICPTPositive Net Change FGENPositive Net Change MLTXPositive Net Change
biotechnology biotechs
Top Analyst Reports for Texas Instruments, Regeneron & Micron Technology
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Texas Instruments Inc. (TXN), Regeneron Pharmaceuticals, Inc. (REGN) and Micron Technology, Inc. (MU).
REGNPositive Net Change TXNNegative Net Change SHWPositive Net Change MUPositive Net Change MCKPositive Net Change FDXPositive Net Change ANETNegative Net Change
biotechnology semiconductor
Amicus (FOLD) Gets Approval in Europe for Pompe Disease Drug
by Zacks Equity Research
Amicus (FOLD) receives approval for Opfolda (miglustat) from the European Commission to treat the adult late-onset Pompe disease.
NVSPositive Net Change FOLDPositive Net Change AKRONegative Net Change
biotechnology medical
Find Stocks to Buy in July that are Gaining More Attention on Wall Street
by Benjamin Rains
Here is how to use our new analyst coverage screen to help investors find stocks to buy in July and for the second half of 2023.
LGNDPositive Net Change
biotechnology pharmaceuticals